AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

STOK · NASDAQ · Biotechnology

Stoke Therapeutics (STOK)

Develops antisense medicines that restore protein expression in severe genetic diseases.

$26.52

vs last close−2.68 (−9.19%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	3	3	4	5	5	23	159	14	11	1	6	9
Cost of revenue	1	1	1	1	0	0	0	0	1	1	1	1
Gross profit	2	2	3	4	5	23	159	14	10	0	5	8
	29	31	31	33	35	36	47	41	53	62	59	74
Research & development	20	21	22	21	22	23	33	26	37	41	40	49
	10	10	10	12	13	13	15	15	15	20	20	25
Selling & marketing	0	−1	−1	−1	0	0	0	0	0	0	0	0
General & administrative	0	11	10	13	13	13	15	15	0	0	0	0
Other expenses	0	0	0	0	0	0	0	0	0	0	−1	0
Operating income	−27	−30	−28	−29	−30	−14	111	−27	−43	−61	−53	−65
	3	3	2	4	4	3	3	4	3	4	3	4
Interest income	3	3	2	4	4	3	3	4	3	4	3	4
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−3	−3	−2	−4	−4	−3	−3	−4	−3	−4	−7	0
Income before tax	−25	−27	−26	−26	−26	−10	114	−23	−40	−58	−50	−62
Income tax expense	0	0	0	0	0	0	1	0	−1	0	0	0
Net income from continuing operations	−25	−27	−26	−26	−26	−10	113	−23	−38	−58	−50	−62
Net income	−25	−27	−26	−26	−26	−10	113	−23	−38	−58	−50	−62
EPS, basic	−$0.55	−$0.60	−$0.57	−$0.46	−$0.47	−$0.18	$1.95	−$0.40	−$0.65	−$0.99	−$0.79	−$0.93
EPS, diluted	−$0.55	−$0.60	−$0.57	−$0.46	−$0.47	−$0.18	$1.90	−$0.40	−$0.65	−$0.99	−$0.79	−$0.93
Weighted average shares, basic	44	45	46	56	56	57	58	58	59	58	63	66
Weighted average shares, diluted	44	45	46	56	56	57	59	58	59	58	63	66
EBITDA	−23	−26	−26	−25	−26	−10	115	−23	−39	−57	−46	−64
Depreciation & amortization	1	1	1	1	1	1	0	0	1	1	1	1
EBIT	−25	−27	−26	−26	−26	−10	114	−23	−40	−58	−47	−65